The purpose of the studies was to confirm the treatment effect and protection account of lubiprostone capsules in Japanese CIC sufferers. The principal endpoint of the efficacy trial, a change from baseline in the number of spontaneous bowel movements at the end of the first week of treatment, was fulfilled by the patients acquiring 24-mcg lubiprostone twice a day . Lubiprostone was been shown to be well-tolerated and there have been no reported severe undesireable effects in either trial. The secondary endpoints of the efficacy trial included the change from baseline in the every week average amount of SBMs at Weeks 2, 3 and 4, and scores in the short form 36 questionnaire and the irritable bowel syndrome standard of living questionnaire.You can consult anything and people will respond.’ – – Member – Penny AddisonsDisease.Net is a trusted leader in online Addison’s disease support and a valuable tool for patients, caregivers, doctors and nurses worldwide.
Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL Allos Therapeutics, Inc. PTCL comprises a biologically diverse band of aggressive, rare blood cancers that have a worse prognosis than most other types of lymphoma, including B-cell lymphoma. Relating to current CHMP guidelines, your final opinion on the re-examination could be issued by the EMA within four to five weeks. KlegermanScalable production of gene therapy vectors: an interview with Frank UbagsSome antibiotics may make MRSA more threatening We believe FOLOTYN has the potential to present a significant new treatment option for sufferers with relapsed or refractory peripheral T-cell lymphoma, a sign for which there are no EMA-approved therapies and no accepted standard of care, said Charles Morris, MB ChB, MRCP, chief medical officer at Allos Therapeutics.